Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.70 |
| ▸ | MAOA | P21397 | 4/20 | 0.70 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.62 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19327341 | 1.00 | MAOB (0.70) | MAOBMAOARELACHRNA7AHR | |
| SCHEMBL19327348 | 0.87 | MAOB (0.74) | MAOBMAOACHRNA7AHR | |
| SCHEMBL19327349 | 0.87 | MAOB (0.74) | MAOBMAOACHRNA7AHR | |
| Hydrochloric Acid SCHEMBL9482931 | 0.85 | MAOA (0.63) | MAOBMAOARELACHRNA7AHR | |
| Hydrochloric Acid SCHEMBL9482411 | 0.85 | MAOA (0.70) | MAOBMAOARELACHRNA7AHR | |
| Hydrochloric Acid SCHEMBL9482938 | 0.85 | MAOA (0.63) | MAOBMAOARELACHRNA7AHR | |
| Hydrochloric Acid SCHEMBL9482375 | 0.85 | MAOA (0.70) | MAOBMAOARELACHRNA7AHR | |
| SCHEMBL9482377 | 0.85 | RELA (0.69) | MAOBMAOARELACHRNA7AHR | |
| SCHEMBL9482387 | 0.85 | RELA (0.69) | MAOBMAOARELACHRNA7AHR | |
| SCHEMBL19327357 | 0.84 | BCHE (0.68) | MAOBMAOARELACHRNA7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260126-A1 | SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION | UNIV OXFORD INNOVATION LTD (GB) | 2017-09-14 | — | — | US | claimed |
| US-20170260126-A1 | SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION | UNIV OXFORD INNOVATION LTD (GB) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260126-A1 | SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION | LDLR, NR1H2, SREBF1 | MAOB 3074/4885MAOA 3740/4885RELA 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.